Joel Palefsky, MD
Member, CFAR Scientific Council
Professor, School of Medicine
Email: joel.palefsky@ucsf.edu
Biography
Joel Palefsky, M.D., C.M., F.R.C.P.(C). Professor of Medicine and Infectious Diseases at the University of California San Francisco School of Medicine. He is an internationally recognized expert on the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections, particularly in the setting of HIV infection. He is the director of the world's first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic Research and Education Center at the UCSF Cancer Center. He is the vice-chair of the National Cancer Institute (NCI)-supported AIDS Malignancy Consortium. He is the chair of the Anal Cancer /HSIL Outcomes Research (ANCHOR) Study, a national multi-site NIH study designed to determine whether treatment of anal cancer precursor lesions prevents the development of anal cancer and to identify biomarkers of progression. He is founder and past president of the International Anal Neoplasia Society and is past president of the International Papillomavirus Society. He is the founder and chairperson of the IPVS International HPV Awareness Campaign.
Displaying 151 - 175 of 366
- Brown C, Krishnan S, Hursh K, Yu M, Johnson P, Page K, Shiboski CH. Dental disease prevalence among methamphetamine and heroin users in an urban setting: a pilot study. J Am Dent Assoc. 2012 Sep; 143(9):992-1001.
- Keller MJ, Burk RD, Xie X, Anastos K, Massad LS, Minkoff H, Xue X, D'Souza G, Watts DH, Levine AM, Castle PE, Colie C, Palefsky JM, Strickler HD. Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection. JAMA. 2012 Jul 25; 308(4):362-9.
- Arbyn M, de Sanjosé S, Saraiya M, Sideri M, Palefsky J, Lacey C, Gillison M, Bruni L, Ronco G, Wentzensen N, Brotherton J, Qiao YL, Denny L, Bornstein J, Abramowitz L, Giuliano A, Tommasino M, Monsonego J. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer. 2012 Nov 01; 131(9):1969-82.
- Palefsky JM. Antiretroviral therapy and anal cancer: the good, the bad, and the unknown. Sex Transm Dis. 2012 Jul; 39(7):501-3.
- Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, McCalmont T, Nayar R, Palefsky JM, Stoler MH, Wilkinson EJ, Zaino RJ, Wilbur DC. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis. 2012 Jul; 16(3):205-42.
- Palefsky J, Berry JM, Jay N. Anal cancer screening. Lancet Oncol. 2012 Jul; 13(7):e279-80; author rreply e280.
- Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, McCalmont T, Nayar R, Palefsky JM, Stoler MH, Wilkinson EJ, Zaino RJ, Wilbur DC. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012 Oct; 136(10):1266-97.
- Palefsky J. HIV protease inhibitors to prevent progression of cervical intraepithelial neoplasia to cervical cancer: therapeutic opportunities and challenges. AIDS. 2012 May 15; 26(8):1035-6.
- Cranston RD, Murphy R, Weiss RE, Da Costa M, Palefsky J, Shoptaw S, Gorbach PM. Anal human papillomavirus infection in a street-based sample of drug using HIV-positive men. Int J STD AIDS. 2012 Mar; 23(3):195-200.
- D'Souza G, Burk RD, Zhong Y, Minkoff H, Massad LS, Xue X, Watts DH, Anastos K, Palefsky JM, Levine AM, Colie C, Castle PE, Strickler HD. Cervicovaginal human papillomavirus (HPV)-infection before and after hysterectomy: evidence of different tissue tropism for oncogenic and nononcogenic HPV types in a cohort of HIV-positive and HIV-negative women. Int J Cancer. 2012 Sep 15; 131(6):1472-8.
- Sharof M. Tugizov, Rossana Herrera, Piri Veluppillai, Deborah Greenspan, Joel M. Palefsky. 46. HIV-induced epithelial–mesenchymal transition in mucosal epithelium facilitates HPV paracellular penetration. Sexual Health. 2013 Jan 1; 10(6):592.
- Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Vardas E, Aranda C, Jessen H, Ferris DG, Coutlee F, Marshall JB, Vuocolo S, Haupt RM, Guris D, Garner EI. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol. 2012 Feb; 19(2):261-7.
- Diouf K, Sawaya GF, Shiboski S, Magure T, Makunike-Mutasa R, Darragh TM, Tuveson J, Chipato T, Palefsky JM, Moscicki AB, Chirenje M, Smith-McCune K. Investigating Potential Associations between Cervical Procedures and HIV Acquisition. ISRN Obstet Gynecol. 2011; 2011:789106.
- Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, Marshall JB, Radley D, Vuocolo S, Haupt RM, Guris D, Garner EI. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011 Oct 27; 365(17):1576-85.
- Guimarães MD, Grinsztejn B, Melo VH, Rocha GM, Campos LN, Pilotto JH, Carmo RA, Palefsky JM. Anal HPV prevalence and associated factors among HIV-seropositive men under antiretroviral treatment in Brazil. J Acquir Immune Defic Syndr. 2011 Aug; 57 Suppl 3:S217-24.
- Moscicki AB, Palefsky JM. Human papillomavirus in men: an update. J Low Genit Tract Dis. 2011 Jul; 15(3):231-4.
- Moreira ED, Palefsky JM, Giuliano AR, Goldstone S, Aranda C, Jessen H, Hillman RJ, Ferris D, Coutlee F, Vardas E, Marshall JB, Vuocolo S, Haupt RM, Guris D, Garner EI. Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults. Hum Vaccin. 2011 Jul; 7(7):768-75.
- Chan PK, Luk AC, Park JS, Smith-McCune KK, Palefsky JM, Konno R, Giovannelli L, Coutlée F, Hibbitts S, Chu TY, Settheetham-Ishida W, Picconi MA, Ferrera A, De Marco F, Woo YL, Raiol T, Piña-Sánchez P, Cheung JL, Bae JH, Chirenje MZ, Magure T, Moscicki AB, Fiander AN, Di Stefano R, Cheung TH, Yu MM, Tsui SK, Pim D, Banks L. Identification of human papillomavirus type 58 lineages and the distribution worldwide. J Infect Dis. 2011 Jun 01; 203(11):1565-73.
- Arron ST, Skewes-Cox P, Do PH, Dybbro E, Da Costa M, Palefsky JM, Derisi JL. Validation of a diagnostic microarray for human papillomavirus: coverage of 102 genotypes. J Nucleic Acids. 2011; 2011:756905.
- Kojic EM, Cu-Uvin S, Conley L, Bush T, Onyekwuluje J, Swan DC, Unger ER, Henry K, Hammer JH, Overton ET, Darragh TM, Palefsky JM, Vellozzi C, Patel P, Brooks JT. Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the study to understand the natural history of HIV/AIDS in the era of effective therapy (the SUN study). Sex Transm Dis. 2011 Apr; 38(4):253-9.
- Sénécal M, Brisson M, Maunsell E, Ferenczy A, Franco EL, Ratnam S, Coutlée F, Palefsky JM, Mansi JA. Loss of quality of life associated with genital warts: baseline analyses from a prospective study. Sex Transm Infect. 2011 Apr; 87(3):209-15.
- Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang YH, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011 Feb 03; 364(5):401-11.
- Krajden M, Cook D, Yu A, Chow R, Mei W, McNeil S, Money D, Dionne M, Karunakaran KP, Palefsky JM, Dobson S, Ogilvie G, Petric M. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol. 2011 Mar; 18(3):418-23.
- Vardas E, Giuliano AR, Goldstone S, Palefsky JM, Moreira ED, Penny ME, Aranda C, Jessen H, Moi H, Ferris DG, Liaw KL, Marshall JB, Vuocolo S, Barr E, Haupt RM, Garner EI, Guris D. External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents. J Infect Dis. 2011 Jan 01; 203(1):58-65.
- Goldstone S, Palefsky JM, Giuliano AR, Moreira ED, Aranda C, Jessen H, Hillman RJ, Ferris DG, Coutlee F, Liaw KL, Marshall JB, Zhang X, Vuocolo S, Barr E, Haupt RM, Guris D, Garner EI. Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men. J Infect Dis. 2011 Jan 01; 203(1):66-74.